realism uk: current treatment pathways for myelofibrosis in the uk
Published 2 years ago • 155 plays • Length 3:20Download video MP4
Download video MP3
Similar videos
-
2:00
the incorporation of immunotherapy into frontline all treatment
-
1:56
incorporating novel agents for myelofibrosis in the pre- and post-transplant settings
-
2:00
the development of anti-fibrotic agents for treating myelofibrosis
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
1:15
exploring the evolving treatment landscape of myelofibrosis
-
1:01
latest advances in myelofibrosis treatment
-
0:53
investigating the place of jak inhibitors in the treatment of myelofibrosis
-
1:47
the evolution of myelofibrosis treatment and modern-day management
-
21:38
drawing the line: the rationale behind blood tube collection order
-
13:48
understanding treatment options for et, pv, and myelofibrosis
-
9:15
andrew kuykendall, md, on symptom improvement outcomes with rusfertide in polycythemia vera
-
1:31
promising agents under investigation for the treatment of myelofibrosis with cytopenia
-
1:07
advances in the treatment of myelofibrosis & the role of transplantation in this space
-
2:05
investigating the efficacy of tp-3654 in patients with myelofibrosis: results from phase i study
-
2:52
jak inhibitor combination therapy for the treatment of myelofibrosis
-
1:28
comorbidities and treatment decisions in myelofibrosis
-
3:48
jak inhibition for the early treatment of myelofibrosis
-
4:16
jak inhibitor selection & sequencing in myelofibrosis
-
2:00
novel treatment strategies in myelofibrosis
-
2:16
current and future treatment approaches for hr-mds
-
6:50
an overview of the immunotherapy landscape in aml: antibodies, bispecifics, & car-t
-
2:16
the current state-of-the-art in mf and pv therapy and future outlooks